Treatment of human immunodeficiency virus - Related lymphoma

Seminars in Hematology

Volumn 38, Issue 4 SUPPL. 10, 2001, Pages 27-31

  Schiffer, Charles A ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INDINAVIR; LAMIVUDINE; MITOXANTRONE; PROTEINASE INHIBITOR; VINCRISTINE; ZIDOVUDINE;

AIDS RELATED COMPLEX; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CONFERENCE PAPER; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0035187092     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0037-1963(01)90041-1     Document Type: Conference Paper

References (18)

1. Improved prognosis in patients with acquired immunodeficiency syndrome-related lymphoma
2. Syngeneic stem cell transplantation for HIV-related lymphoma
3. The management of adult aggressive non-Hodgkin's lymphomas
4. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma
5. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among HIV-1-infected individuals
6. Tumor lysis syndrome: Pathogenesis and management
7. Advanced Hodgkin's disease in a pregnant HIV seropositive woman: Favorable mother and baby outcome following, combined anticancer and antiretroviral therapy
8. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy
9. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy
10. Intensive chemotherapy (LHNIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma
11. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin's lymphoma
12. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center
13. Pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanoside and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
14. Infusional cyclo-phosphamide, doxorubicin, and etoposide in patients with relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule-dependent effect favoring infusional administration of chemotherapy
15. Infusional cyclo-phosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: A follow-up report of a highly active regimen
16. Human immunodeficiency virus-related non-Hodgkin lymphoma: Activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients
17. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus
18. Impact of HAART on the clinical management of AIDS-related cancers